News Release

Latest News

February 2, 2015: Summary of Consolidated Financial Results (For the Third Quarter Ended Dec 31,2014)［Japanese Standard］
February 2, 2015: Consolidated Financial Results (For the Third Quarter Ended Dec 31,2014)- Supplementary Information
December 1, 2014: Release of Flutiform® 50 Aerosol - 120 inhalations, Flutiform® 125 Aerosol - 120 inhalations , a combination drug for asthma treatment
November 27, 2014: Signing of Co-Marketing Agreement on Investigational Antiallergic Agent, Desloratadine for Japan
November 4, 2014: Summary of consolidated financial results (November 4, 2014)
November 4, 2014: Consolidated Financial Results (For the Second Quarter Ended september 30,2014)- Supplementary Information
October 10, 2014: Kyorin Pharmaceutical and R-Pharm Reach Agreement in Russia and neighboring nations for Activities Related to the Development and Marketing of Imidafenacin
September 10, 2014: EISAI AND KYORIN ENTER INTO AGREEMENT CONCERNING COMPOUND LIBRARY USE FOR THE DEVELOPMENT OF NEW ANTIBACTERIAL AGENTS
July 29, 2014: Summary of Consolidated Financial Results (For the First Quarter Ended June 30, 2014) [Japanese Standard]
July 22, 2014: Kyorin signed a License Agreement with Merck on Vibegron for Overactive Bladder in Japan
July 1, 2014: Gene-Therapy Product for the Treatment of Malignant Pleural Mesothelioma adopted as Next generation Technology Transfer Program (NexTEP) by JST
May 9, 2014: Summary of Consolidated Financial Results (For the fiscal year ended March 31, 2014) [Japanese Standard]
February 4, 2014: Third Quarter Consolidated Financial Results for the Ending Fiscal Year March 31, 2014
February 4, 2014: Summary of Consolidated Financial Results(For the Third Quarter Ended December 31, 2013) [Japanese Standard]
November 19, 2013: Release of Flutiform, a combination drug for asthma treatment
November 5, 2013: Summary of Consolidated Financial Results (For the Second Quarter Ended September 30, 2013)　[Japanese Standard]
October 17, 2013: Kyorin and Kissei announce the initiation of a Phase I clinical trial of KRP-EPA605/ KEA-0447 for the treatment of overactive bladder
September 20, 2013: Approval received for Flutiform, a combination drug for asthma treatment
July 30, 2013: Consolidated Financial Results (For the First Quarter Ended June 30,2013)- Supplementary Information
July 30, 2013: Summary of Consolidated Financial Results (For the First Quarter Ended June 30,2013)［Japanese Standard］
May 9, 2013: Summary of Consolidated Financial Results(For the fiscal year ended March 31, 2013)
May 9, 2013: Financial Results for the Fiscal 2012, the Year Ended March 31, 2013- Supplementary Information
March 25, 2013: Approval Received for PENTASA® Suppositories 1g,a Drug for Ulcerative colitis.
February 4, 2013: Consolidated Financial Results (For the Third Quarter Ended December 31,2012)- Supplementary Information
February 4, 2013: Summary of Consolidated Financial Results (For the Third Quarter Ended December 31,2012)［Japanese Standard］
November 7, 2012: Consolidated Financial Results (For the Second Quarter Ended september 30,2012)- Supplementary Information
November 7, 2012: Summary of Consolidated Financial Results (For the Second Quarter Ended september 30,2012)［Japanese Standard］
October 9, 2012: Announcement regarding transfer of "Pekiron Cream 0.5%" topical antifungal medication business.
September 25, 2012: Application filed for KRP-108, an Anti-asthmatic Treatment, in Japan
July 31, 2012: Summary of Consolidated Financial Results(For the First Quarter Ended June 30, 2012)
July 31, 2012: First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2013
May 28, 2012: Establishment of a Subsidiary
May 28, 2012: Announcement Regarding Transfer/Acquisition of MSD Shiga Plant
May 9, 2012: Financial Results for the Fiscal 2011, the Year Ended March 31, 2012- Supplementary Information
May 9, 2012: Summary of Consolidated Financial Results(For the fiscal year ended March 31, 2012)
April 20, 2012: Launch of "AIPHAGANR Ophthalmic Solution 0.1%" for the treatment of Glaucoma / Ocular Hypertension, in Japan
February 3, 2012: Third Quarter Consolidated Financial Results for the Ending Fiscal Year March 31, 2012
February 3, 2012: Summary of Consolidated Financial Results(For the Third Quarter Ended December 31, 2011) [Japanese Standard]
November 8, 2011: Kyorin Pharmaceutical and Daiichi Sankyo Brasil Reach Agreement in Brazil for Activities Related to the Development and Marketing of Imidafenacin
November 8, 2011: Summary of Consolidated Financial Results (For the Second Quarter Ended september 30,2011)［Japanese Standard］
November 8, 2011: Consolidated Financial Results (For the Second Quarter Ended september 30,2011)- Supplementary Information
August 22, 2011: First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2012
August 11, 2011: Summary of Consolidated Financial Results(For the First Quarter Ended June 30, 2011)
May 11, 2011: Financial Results for the Fiscal 2010, the Year Ended March 31, 2011- Supplementary Information
May 11, 2011: Summary of Consolidated Financial Results(For the fiscal year ended March 31, 2011)
April 5, 2011: Release of "Uritos® OD Tablets 0.1mg" a Drug for Overactive Bladder
February 24, 2011: Kyorin signed a License Agreement with Almirall on COPD Therapeutic Agent "Aclidinium Bromide" for Japan Territory
February 21, 2011: KYORIN Group's Participation in Environmental Hygiene
February 15, 2011: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2011
February 8, 2011: Summary of Consolidated Financial Results (For the Third Quarter Ended December 31, 2010) [Japanese Standard]